40
Participants
Start Date
August 31, 2013
Primary Completion Date
November 30, 2014
Study Completion Date
October 31, 2015
Interleukin-2
Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing
Monash University
OTHER
Peking University People's Hospital
OTHER